Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-20-003039
Filing Date
2020-02-26
Accepted
2020-02-26 20:26:00
Documents
1
Period of Report
2020-02-21

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3812
  Complete submission text file 0001493152-20-003039.txt   5467
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Issuer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 7389 Services-Business Services, NEC

Mailing Address IROQUOIS CAPITAL MANAGEMENT LLC 205 EAST 42ND ST - 20TH FL. NEW YORK NY 10017
Business Address
Silverman Joshua (Reporting) CIK: 0001524858 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51353 | Film No.: 20658025